In addition to these three meta-analyses, a pooled analysis38of seven RCTs112, 114, 125, 126, 127, 128, 129reported no association between SGLT2 inhibitors and VTE risk in T2DM patients, though limited details were provided regarding this outcome. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.